COX-2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib : A quantitative immunohistochemical analysis of RTOG C0128

International Journal of Gynecological Cancer

Volumn 23, Issue 1, 2013, Pages 176-183

  Doll, Corinne M ^a   Winter, Kathryn ^b   Gaffney, David K ^c   Ryu, Janice K ^d   Jhingran, Anuja ^e   Dicker, Adam P ^f   Weidhaas, Joanne B ^g   Miller, Brigitte E ^h   Magliocco, Anthony M ⁱ  

^a UNIVERSITY OF CALGARY   (Canada)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d Radiological Associates of Sacramento Medical Group Inc   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h WAKE FOREST SCHOOL OF MEDICINE   (United States)

ⁱ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

CD34; Cervical cancer; COX 2; Predictive markers; RTOG C0128

Indexed keywords

CD34 ANTIBODY; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 2; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR BIOPSY; UTERINE CERVIX CANCER;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II AS TOPIC; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PYRAZOLES; SULFONAMIDES; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84872324978     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182791efc     Document Type: Article

References (25)

1. Vale C, Tierney JF, Stewart LA, et al. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26:5802-5812.
2. Masunaga R, Kohn H, Dhar D, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res. 2000;6:4064-4068.
3. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705-716.
4. Gaffney D, Holden J, Davis M, et al. Increased cyclooxygenase-2 expression correlated with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2001;49:1213-1217.
5. Chen HW, Wu-Chou S, Cheng-Yang C, et al. Increased expression of nitric oxide synthase and cyclooxygenase-2 is associated with poor survival in cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:1093-1100.
6. Lindstrom AK, Stendahl U, Tot T, et al. Predicting the outcome of squamous cell carcinoma of the uterine cervix using combinations of individual tumor marker expressions. Anticancer Res. 2007;27:1609-1616.
7. Ferrandina G, Lauriola L, Distefano M, et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical patients. J Clin Oncol. 2002;20:973-981.
8. Masferrer J, Leahy K, Koki A, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60:1306-1311.
9. Kishi K, Petersen S, Petersen C, et al. Preferential enhancement of tumor radioresponse by a cycloocygenase-2 inhibitor. Cancer Res. 2000;60:1326-1331.
10. Mao X, Wang X, Xu L. COX-2 expression in gastric cancer and its relationship with angiogenesis using tissue microarray. World J Gastroenterol. 2007;13:3466-3471.
11. Hlatky L, Hahnfeltd P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst. 2002;94:883-893.
12. Viera SC, Zeferino LC, Da Silva BB, et al. Quantification of angiogenesis in cervical cancer: a comparison among three endothelial cell markers. Gynecol Oncol. 2004;93:121-124.
13. Gaffney DK, Winter K, Dicker AP, et al. Efficacy and patterns of failure for locally advanced cancer of the cervix treated with Celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. Int J Radiat Oncol Biol Phys. 2007;69:111-117.
14. Herrera F, Chan P, Doll C, et al. A prospective phase I/II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment. Int J Radiat Oncol Biol Phys. 2007;67:97-103.
15. Mohammadianpanah M, Razmjou-Ghalaei S, Shafizad A, et al. Efficacy and safety of concurrent chemoradiation with weekly cisplatin ± low-dose celecoxib in locally advanced undifferentiated nasopharyngeal carcinoma: a phase II/III clinical trial. J Cancer Res Ther. 2011;7:442-447.
16. Groen HJ, Sietsma H, Vincent A, et al. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol. 2011;29:4320-4326.
17. Edelman MJ, Watson D, Wang X, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-Cancer and Leukemia Group B Trial 30203. J Clin Oncol. 2008;26:848-855.
18. Fidler MJ, Argiris A, Patel JD, et al. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res. 2008;14:2088-2094.
19. Rini BI, Weinberg V, Dunlap S, et al. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer. 2006;106:566-575.
20. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002;8:1323-1327.
21. Doll CM, Prystajecky M, Eliasziw M, et al. Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone. Radiother Oncol. 2010;97:352-359.
22. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons; 1980.
23. Altorki NK, Christos P, Port JL, et al. Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial. J Thorac Oncol. 2011;6:1121-1127.
24. Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide and with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000;18:623-631.
25. Ancuta C, Ancuta E, Zucon-Eloae FL, et al. Neoangiogenesis in cervical cancer: focus on CD34 assessment. Rom J Morphol Embryol. 2010;51:289-294.